At least 48 hospitals lost their eligibility for 340B drug discounts for reasons related to the COVID-19 pandemic and are seeking reinstatement to the 340B program, the U.S. Health Resources and Services Administration (HRSA) said this week.
April 14 was the deadline for such hospitals that want to reenroll in 340B to attest to HRSA that the public health emergency (PHE) disrupted their admission patterns to the point that their Medicare disproportionate share (DSH) adjustment percentage fell below the level needed to qualify for 340B drug pricing. Congress passed a spending bill last month with language to help such hospitals get back into 340B and others that similarly may lose their eligibility through the end of this year.
At least 48 hospitals lost their eligibility for 340B drug discounts for reasons related to the COVID-19 pandemic and are seeking reinstatement to the 340B program, HRSA says.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
